Silke Brandt-Schmidt serves as SVP of Program Development at CatalYm. Before joining CatalYm, she successfully steared early and late-phase immunotherapy programs with increasing levels of responsibility at Affimed and prior to that at Merck KGaA. Silke led a bi-specific molecule through all stages of clinical development, due diligence, contracting, and alliance building in a co-development and co-commercialization partnership between Merck KGaA and GSK. Silke brings a wealth of international program development expertise across a broad range of innovative therapeutic approaches such as vaccines, antibodies, bi-specific molecules, cell therapies and extensive regulatory and CMC expertise to CatalYm. She has a track record in orchestrating cross-functional teams delivering on integrated development plans, with a particular focus on innovative molecules in Oncology and Immuno-Oncology. Silke holds a PhD in Chemistry from the University of Kiel and an Advanced Certificate in Molecular Biology from the University of Hamburg.

WordPress Cookie Notice by Real Cookie Banner